November 29, 2025 a 07:43 pm
INCY: Fundamental Ratio Analysis - Incyte Corporation
Incyte Corporation, a leader in the biotechnology industry, offers a diversified portfolio of proprietary therapeutics. Recently, the company has shown steady financial performance, showcasing strong fundamentals despite the competitive market. Investors may find its strategic partnerships and pipeline promising for future growth.
Fundamentals Rating
Incyte Corporation demonstrates a solid foundation with a fundamentals rating of A-. Key metrics reflect the company's efficient operations and promising profitability potential.
| Category | Score | Visualization |
|---|---|---|
| Overall Score | 4 | |
| Discounted Cash Flow | 4 | |
| Return On Equity | 5 | |
| Return On Assets | 5 | |
| Debt To Equity | 3 | |
| Price To Earnings | 2 | |
| Price To Book | 2 |
Historical Rating
Comparing the current scores with the historical data can provide insights into the company's performance trends over time.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-11-28 | 4 | 4 | 5 | 5 | 3 | 2 | 2 |
| Previous Date | 0 | 4 | 5 | 5 | 3 | 2 | 2 |
Analyst Price Targets
Analyst projections provide a range of expectations on Incyte Corporation's stock potential.
| High | Low | Median | Consensus |
|---|---|---|---|
| 115 | 68 | 95 | 93.17 |
Analyst Sentiment
Understanding the distribution of analyst recommendations can give an impression of the overall market sentiment towards Incyte Corporation.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 23 | |
| Hold | 18 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Incyte Corporation presents a promising investment opportunity with strong fundamentals and a robust therapeutic pipeline. The current analyst consensus rating is a 'Buy', suggesting confidence in the company's near-term prospects. Risks may include competitive pressures and clinical trial outcomes. Overall, investors might find Incyte a compelling choice in the biopharmaceutical sector, underpinned by solid financial health and strategic collaborations.